Katherine Stueland Sells 10,559 Shares of GeneDx Holdings Corp. (NASDAQ:WGS) Stock

GeneDx Holdings Corp. (NASDAQ:WGS) CEO Katherine Stueland sold 10,559 shares of the business’s stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $96.71, for a total value of $1,021,160.89. Following the sale, the chief executive officer now directly owns 14,865 shares in the company, valued at approximately $1,437,594.15. The trade was a 41.53 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Katherine Stueland also recently made the following trade(s):

• On Thursday, March 13th, Katherine Stueland sold 1,078 shares of GeneDx stock. The stock was sold at an average price of $89.44, for a total value of $96,416.32.
• On Monday, March 10th, Katherine Stueland sold 2,731 shares of GeneDx stock. The stock was sold at an average price of $94.73, for a total value of $258,707.63.
• On Wednesday, January 29th, Katherine Stueland sold 1,657 shares of GeneDx stock. The stock was sold at an average price of $78.48, for a total value of $130,041.36.
• On Tuesday, January 7th, Katherine Stueland sold 51,420 shares of GeneDx stock. The shares were sold at an average price of $94.48, for a total value of $4,858,161.60.
• On Thursday, January 2nd, Katherine Stueland sold 18,006 shares of GeneDx stock. The shares were sold at an average price of $78.18, for a total value of $1,407,709.08.

GeneDx Price Performance

Shares of NASDAQ:WGS opened at $90.79 on Wednesday. The company’s fifty day moving average is $84.57 and its two-hundred day moving average is $70.78. The company has a quick ratio of 2.27, a current ratio of 2.40 and a debt-to-equity ratio of 0.25. GeneDx Holdings Corp. has a 12-month low of $7.72 and a 12-month high of $115.60. The company has a market cap of $2.55 billion, a P/E ratio of -46.32 and a beta of 1.91.

GeneDx (NASDAQ:WGS) last announced its earnings results on Tuesday, February 18th. The company reported $0.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.04 by $0.66. GeneDx had a negative net margin of 17.12% and a positive return on equity of 3.33%. The company had revenue of $95.64 million for the quarter, compared to the consensus estimate of $82.24 million. Equities analysts expect that GeneDx Holdings Corp. will post 0.97 earnings per share for the current fiscal year.

Institutional Trading of GeneDx

Several large investors have recently added to or reduced their stakes in WGS. California State Teachers Retirement System grew its holdings in shares of GeneDx by 13.3% during the 4th quarter. California State Teachers Retirement System now owns 11,384 shares of the company’s stock valued at $875,000 after acquiring an additional 1,335 shares in the last quarter. Polar Asset Management Partners Inc. purchased a new position in shares of GeneDx during the 4th quarter valued at $1,007,000. Palisades Investment Partners LLC purchased a new position in shares of GeneDx during the 4th quarter valued at $6,425,000. Castleark Management LLC purchased a new position in shares of GeneDx during the 4th quarter valued at $4,743,000. Finally, PharVision Advisers LLC purchased a new position in shares of GeneDx during the 4th quarter valued at $301,000. 61.72% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research analysts have issued reports on WGS shares. TD Cowen upped their price target on GeneDx from $75.00 to $118.00 and gave the company a “buy” rating in a report on Tuesday, January 7th. The Goldman Sachs Group upped their price target on GeneDx from $70.00 to $80.00 and gave the company a “neutral” rating in a report on Wednesday, February 19th. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $72.33.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.